20年初心不改，20年风雨兼程，20年执着追求。

2019年度中医内科学教育部重点实验室全体成员携手奋进，锐意拼搏，论文发表又创新高。

共计发表学术论文96篇，其中SCI收录合计34篇，影响因子合计110.55，单篇最高影响因子6.971；中文期刊62篇，均为核心期刊。

以东迁通州院区为契机，重点实验室全体中医药人将不忘初心、牢记使命、传承精华、守正创新、人心向学、和合共进，继续创造新成绩，续写科技新篇章！

科技为民，奋斗有我！

英 文 文 章

1.  心血管病方向

[1] YangX，He T，HanS，Zhang X，SunY，Xing Y，ShangH*.TheRole of Traditional Chinese Medicine in the Regulation of Oxidative Stress inTreating Coronary Heart Disease. Oxid Med Cell Longev, 2019. 2019: p. 3231424.（SCI收录，IF4.868）.............................................................................................1

[2] An N，GaoY^#，Si Z，ZhangH，Wang L，TianC，Yuan M，YangX，Li X，ShangH，Xiong X，XingY.Regulatory Mechanisms of the NLRP3 Inflammasome, a Novel Immune-InflammatoryMarker in Cardiovascular Diseases. Front Immunol, 2019. 10: p. 1592.（SCI收录，IF4.716）.................................................................2

[3] Zhang H, Gao YH, Wang LQ, Tian L,An N, Yang XY, Tian C, Yuan MC, Xiong XJ, Liu N, Shang HC*, Xing YW.Doesheart failure increase the risk of incident cancer? Ameta-analysis andsystematic review.Heart failure reviews,2019,2019:1-7（SCI收录，IF4.015）..............................................................................................3

[4] Yang T，LuZ，Wang L，ZhaoY，Nie B，XuQ，Han X，LiT，Zhao J，ChengW，Wang B，WuA，Zhu H，MengW，Shang H*，ZhaoM*.DynamicChanges in Brain Glucose Metabolism and Neuronal Structure in Rats with HeartFailure. Neuroscience, 2019. 424: p. 34-44.（SCI收录，IF3.244）.........................4

[5] Yang Y，HuD，Sacher F，KusanoK. F，Li X，Barajas-Martinez,H，Hocini, M，LiY，Gao Y，ShangH*，Xing Y. Meta-Analysis of RiskStratification of SCN5A With Brugada Syndrome: Is SCN5A Always a Marker of LowRisk? Front Physiol, 2019. 10: p. 103.（SCI收录，IF3.201）.....................................................5

[6] Qiu R，ZhongC，Han S，HeT，Huang Y，GuanM，Hu J，LiM，Lin Y，ChenJ，Shang H*.Development of a core outcome setfor myocardial infarction in clinical trials of traditional Chinese medicine: astudy protocol. BMJ Open, 2019. 9(12): p. e032256.（SCI收录，IF2.376）................................................................6

[7] Li M，WangX，Li X，ChenH，Hu Y，ZhangX，Tang X，MiaoY，Tian G，ShangH*.Statinsfor the Primary Prevention of Coronary Heart Disease. Biomed Res Int, 2019.2019: p. 4870350.（SCI收录，IF2.197）................................................7

[8] H Ya, Wu A*, Lou L, Zhang D,Nie B,Zhao Yu , Liu K,Zhao M ,Shang H.Wenxin Granules Influence theTGFβ-P38/JNK MAPK Signaling Pathway and Attenuate the Collagen Deposition inthe Left Ventricle of Myocardial Infarction Rats.Cardiology Research andPractice,2019,Article ID 3786024.（SCI收录，IF2.14）...................8

[9] Chen H，LouL，Zhang D，ZhaoY，Zhao J，LiC，Huang Y，LiuK，Zhao M，WuA*.Qiliqiangxin Capsule Improves Cardiac Function and Attenuates CardiacRemodeling by Upregulating miR-133a after Myocardial Infarction in Rats. EvidBased Complement Alternat Med, 2019. 2019: p. 7528214.（SCI收录，IF1.984）...........................................................................................................................9

[10] Zhang XY, Sun Y, Yang XY, Hu JY,Zheng R, Chen SQ, Li M, Li CY, Jiang Y, Liu S, Zhao C, Xing YW, Shang HC*.Effectof Chinese Medicine on No or Slow Reflow after Percutaneous CoronaryIntervention in Myocardial Infarction Patients: A Systematic Review andMeta-Analysis.Chin J Integr Med.2019,2019:1-8（SCI收录，IF1.445）....................................................................................................................10

2.       脑血管病方向

[11] Zhang H,Xing Y,Chang J,Wang L,AnN,Tian C,Yuan M,Yang X,Shang H,Gao Y*,Gao Y*.Efficacy and Safety ofNaoShuanTong Capsule in the Treatment of Ischemic Stroke: A Meta-Analysis. FrontPharmacol, 2019. 10: p. 1133.（SCI收录，IF3.845）....................................................................................................................11

[12] Wang Y，LiuC，Wang H，JiangY，Wang P*，ShangH*.SystematicReview of Basic Research on Alzheimer's Disease with Shen Zhi Ling Oral Liquid.Evid Based Complement Alternat Med, 2019. 2019: p. 8216714.（SCI收录，IF2.064）.........................................................................................................................12

3. 肾脏病、内分泌、风湿免疫方向

[13] LiuWJ,GanY,Huang W F,Wu H L,Zhang X Q,Zheng H J,Liu H F. Lysosome restoration toactivate podocyte autophagy: a new therapeutic strategy for diabetic kidneydisease. Cell Death Dis, 2019. 10(11): p. 806.（SCI收录，IF5.959）.......13    

[14] Zheng H J,Guo J,Jia Q,Huang YS,Huang W J,Zhang W,Zhang F,Liu W J*,Wang Y.The effect of probiotic andsynbiotic supplementation on biomarkers of inflammation and oxidative stress indiabetic patients: A systematic review and meta-analysis of randomizedcontrolled trials. Pharmacol Res, 2019. 142: p. 303-313.（SCI收录，IF5.574）............................................................................................14

[15] Huang WJ, Liu W J,Xiao Y H,Zheng H J,XiaoY,Jia Q,Jiang H X,Zhu Z B,Xia C H,Han X T,Sun R X,Nan H,Feng Z D,Wang S D,ZhaoJ X.Tripterygium and its extracts for diabetic nephropathy: Efficacy andpharmacological mechanisms. Biomed Pharmacother, 2020. 121: p. 109599.（SCI收录，IF3.743）.................................15

[16]  Zhao Y, Zhang W,Jia Q,Feng Z,GuoJ,Han X,Liu Y,Shang H,Wang Y,Liu WJ*.

High Dose Vitamin E Attenuates DiabeticNephropathy via Alleviation of Autophagic Stress. Front Physiol, 2018. 9: p.1939.（SCI收录，IF3.201）..........16

[17] Wang X,Zhao L,Ajay A K,Jiao B,ZhangX,Wang C,Gao X,Yuan Z,Liu H,Liu WJ*. QiDiTangShen Granules ActivateRenal Nutrient-Sensing Associated Autophagy in db/db Mice. Front Physiol, 2019.10: p. 1224.（SCI收录，IF3.201）.........................................................................................................................17

[18] Cui FQ, Tang L,Gao Y B,Wang YF,Meng Y,Shen C,Shen Z L,Liu Z Q,Zhao W J,Liu WJ*.Effect of BaoshenfangFormula on Podocyte Injury via Inhibiting the NOX-4/ROS/p38 Pathway in DiabeticNephropathy. J Diabetes Res, 2019. 2019: p. 2981705.（SCI收录，IF3.04）...............................................................................18

[19] Zheng Q, Yang H,Liu W,SunW,Zhao Q,Zhang X,Jin H,Sun L.Comparative efficacy of 13 immunosuppressiveagents for idiopathic membranous nephropathy in adults with nephrotic syndrome:a systematic review and network meta-analysis. BMJ Open, 2019. 9(9): p.e030919.（SCI收录，IF2.376）............................................19

4. 循证评价方向

[20] Song Y.,Yao C,Yao Y,Han H,Zhao X,YuK,Liu L,Xu Y,Liu Z,Zhou Q,Wang Y,Ma Z,Zheng Y,Wu D,Tang Z,Zhang M,Pan S,ChaiY,Song Y,Zhang J,Pan L,Liu Y,

YuH,Yu X,Zhang H,Wang X,Du Z,Wan X,Tang Y,Tian Y,Zhu Y,Wang H,Yan X,Liu Z,ZhangB,Zhong N,Shang H*,Bai C.XueBiJing Injection Versus Placebo for CriticallyIll Patients With Severe Community-Acquired Pneumonia: A Randomized ControlledTrial. Crit Care Med, 2019. 47(9): p. e735-e743.（SCI收录，IF6.971）........................................................................................................................20

[21] Qin QF,Li X J,Li YS,Zhang W K,TianG H,Shang HC*,Tang HB.AMPK-ERK/CARM1 Signaling Pathways Affect Autophagyof Hepatic Cells in Samples of Liver Cancer Patients. Front Oncol, 2019. 9: p.1247.（SCI收录，IF4.137）......21

[22] Wang Y,Liu Y^#,ZhouK,Bauer B A,Liu B,Su T,Mo Q,Liu Z.The duration of acupuncture effects and itsassociated factors in chronic severe functional constipation: secondaryanalysis of a randomized controlled trial. Therap Adv Gastroenterol, 2019. 12:p. 1756284819881859.（SCI收录，IF3.961）.................................................22

[23] Li B, Feng S, Wu ZH, Kwong JSW, HuJ, Wu N, Tian GH, Shang HC*, Qiu GX.Adverse drug reactions of YunnanBaiyao capsule: a multi-center intensive monitoring study in China. Ann TranslMed, 2019. 7(6): p. 118.（SCI收录，IF3.689）.........................................................................................................................23

[24]  Li J, Niu J, Yang M, Ye P, Zhai J,Yuan W, Feng L, Tian G, Hu J, Wang Y, Shang H*.Using single-patient(n-of-1) trials to determine effectiveness of traditional Chinese medicine onchemotherapy-induced leukopenia in gastric cancer: a feasibility study.Annalsof Translational Medicine,2019,7: p.124.（SCI收录，IF3.689）.....24

[25]  ZhengR, Wang H, Liu Z, Wang X, Li J, Lei X, Fan Y, Liu S, Feng Z, Shang H*.Areal-world study on adverse drug reactions to Xuebijing injection: hospitalintensive monitoring based on 93 hospitals (31,913 cases). Ann Transl Med,2019. 7(6): p. 117.（SCI收录，IF3.689）.........................................................................25

[26]Li C, Wang P, Zhang L, Li M, Lei X, Liu S, Feng Z, Yao Y, Chang B, Liu B, ShangH*.Efficacy and safety of Xuebijing injection (a Chinese patent) forsepsis: a meta-analysis of randomized controlled trials.Journal of Ethnopharmacology.2018.5.512-521.（SCI收录，IF3.414）................................................26

[27] Sun Y,Liu Y^#,LiuS,Wang W,Liu Z.Electroacupuncture for women with urgency-predominant mixedurinary incontinence: secondary analysis of a randomized noninferiority trial.World J Urol, 2019.（SCI收录，IF2.761）.............................27

[28] Jin Y, Li Z, Han F, Huang D, HuangQ, Cao Y, Weng H, Zeng XT, Wang X, Shang HC*. Barriers and enablers forthe implementation of clinical practice guidelines in China: a mixed-methodstudy. BMJ Open, 2019. 9(9): p. e026328.（SCI收录，IF2.376）........................................................................................................28

[29] Qiu R, Hu J, Huang Y, Han S, Zhong C, LiM, He T, Lin Y, Guan M, Chen J, Shang H*. Outcome reporting fromclinical trials of non-valvular atrial fibrillation treated with traditionalChinese medicine or Western medicine: a systematic review. BMJ Open, 2019.9(8): p. e028803.（SCI收录，IF2.376）...................................29

[30]  LiJ, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, Li B, Wang Q, Wang XQ, Wei D, TianJH, Ma B, Yang KH, Dai M, Tian GH, Shang HC*. CONSORT extension forreporting N-of-1 trials for traditional Chinese medicine (CENT for TCM) :Recommendations, explanation and elaboration. Complement Ther Med, 2019. 46: p.180-188.（SCI收录，IF1.979）..........................................................30

[31] Sun Y,Liu Y^#,SuT,Yuan J,Liu Z,Medical, epidemiologic, and social aspects of aging urinaryincontinence questionnaire: Study protocol for the translation and validationof a Chinese language version. Medicine (Baltimore), 2019. 98(44): p. e17719.（SCI收录，IF1.87）..................................................................................31

5. 中药药理及作用机制方向

[32] Lin S,Nie B^#,SongK,Ye R,Yuan Z.Pinelliae Rhizoma Praeparatum Cum Alumine Extract: Sedative andHypnotic Effects in Mice and Component Compounds.Biomed Res Int.2019.6198067.（SCI收录，IF2.197）......................32

[33] Mana L,Feng H,Dong Y,Wang Y,ShiJ,Tian J,Wang P*.Effect of Chinese herbal compound GAPT on the earlybrain glucose metabolism of APP/PS1 transgenic mice.Int J ImmunopatholPharmacol.2019.33.2058738419841482（SCI收录，IF2.18）...........................................................................................................................33

[34] Wang Y,Wang P*,Chen F,LuluM,Huang S,Liu Z.Potential synaptic plasticity-based Shenzhiling oral liquid fora SAD Mouse Model.Brain Behav.2019.9(9).e01385.（SCI收录，IF2.072）............................................................................................34

备注：#：共同第一作者；*：通讯作者

中 文 文 章

1. 心血管病方向

[1] 李敏,孙杨,邱瑞瑾,李承羽,陈诗琪,商洪才*.冠心病相关中医证候DNA甲基化研究进展[J].中国中西医结合杂志,2019,3904:509-512.................................35

[2] 袁梦晨,高永红,王阶,赵步长,邢雁伟,李军,陈恒文,赵涛,赵超,王益民.丹红注射液对急性心肌梗死PCI围手术期心功能和TIMI血流影响的Meta分析[J].中国实验方剂学杂志,,2019:1-6.............................................................................36

[3] 韩松洁,邱瑞瑾,何天麦,杨新宇,黄涯,商洪才*.阿托伐他汀对心肌梗死后心力衰竭临床疗效的系统评价[J].药物评价研究,2019,4206:1224-1234.............37

[4] 黄涯,何天麦,吴爱明*,商洪才*.稳心颗粒干预心肌缺血大鼠电生理重构的系统评价[J].世界中医药,2019,1410:2557-2562.................................................38

[5] 张晓雨,钟长鸣,关曼柯,何天麦,韩松洁,孙杨,郑蕊,胡嘉元,石兆峰,杨欣宇,代倩倩,商洪才*.心肌梗死中医防治临床研究证据图[J].世界中医药,2019,1410:2537-2544+2551...............................................................................39

[6] 成文堃,赵明镜,祁轶斐,娄利霞,吴爱明,赵一舟,任学娇,朱珂,张冬梅*.活血益气方促缺氧人脐静脉内皮细胞迁移及其相关调控基因mRNA表达的拆方研究[J].中西医结合心脑血管病杂志,2019,1713:1951-1955.....................................40

[7] 朱珂,娄利霞,高永红,国倩倩,吴丹丹,高毅洁,王曼曼,张冬梅*.扶正化瘀方对血管紧张素Ⅱ诱导的心肌成纤维细胞miR-29b-5p表达的影响[J].医学综述,2019,2513:2689-2694.........................................................................................41

[8] 朱珂,娄利霞,祁轶斐,高永红,李春红,国倩倩,吴丹丹,张冬梅*.从基质代谢角度探讨扶正化瘀方抗心肌纤维化的细胞分子机制[J].中国医药导报,2019,1623:12-15.................................................................................................42

[9] 祁轶斐,朱珂,任学娇,娄利霞,吴爱明,国倩倩,吴丹丹,成文堃,张冬梅*.扶正化瘀胶囊对心肌梗死后心肌纤维化大鼠微小RNA-29家族表达的影响[J].环球中医药,2019,1206:839-844.....................................................................................43

[10] 陆梓雯,赵明镜*,王蕾,杨涛,孟伟,成文堃,李彤,王保福,杨京京,李洋.慢性心力衰竭病人认知障碍特点及评价方法[J].中西医结合心脑血管病杂志,2019,1716:2440-2443........................................................................................44

[11] 成文堃,赵明镜*,王蕾,陆梓雯,杨涛,杨京京,李彤,王保福,李洋.心力衰竭底物代谢重构模式及其机制的研究进展[J].中国实验方剂学杂志,,:1-15.......45

[12] 陆梓雯,赵明镜*,王蕾,杨涛,赵一舟,仇琪,成文堃,李彤,王保福,杨京京,李洋,蒋洋洋.慢性心力衰竭大鼠脑血流量变化及其一氧化氮合酶机制[J].中西医结合心脑血管病杂志,2019:1-6...........................................................................46

2. 脑血管病方向

[13] 白晶,高颖*,高永红.培元通脑胶囊对脑缺血低灌注大鼠前额叶葡萄糖代谢的影响[J].环球中医药,2019,1205:666-670........................................................47

[14] 王晓峰,田超,张岩,袁梦晨,张涵莱,王丽琴,安娜,高永红*.脑血疏口服液对脑出血模型大鼠脑组织ZO-1和AQP4表达的影响[J].中国医药导报,2019,1616:8-12..................................................................................................48

[15] 白晶,高永红,高颖.培元通脑胶囊对CI大鼠工作记忆及海马内谷氨酸及其受体表达的影响[J].世界中医药,2019,1409:2280-2284.....................................49

[16] 王丽琴,安娜,田超,袁梦晨,张涵莱,孙逸坤,高永红*.活血化瘀法治疗脑出血作用机制实验研究进展[J].中国实验方剂学杂志,,:1-7.................................50

[17] 田超,玛娜璐璐,袁梦晨,王丽琴,安娜,张涵莱,邢雁伟,孙逸坤,高永红*.清开灵对小胶质细胞缺氧活化诱导的脑微血管内皮细胞Toll样受体4、gp91(phox)和闭锁小带蛋白-1表达的影响[J].中国康复理论与实践,2019,11:1303-1308............................................................................................51

[18] 李春红,王婕,吴爱明,陈慧洋,张婷,马喆,高永红,娄利霞*.磷酸川芎嗪对血管紧张素Ⅱ诱导的H9c2细胞肥大的影响及其机制的研究[J].中国医药导报,2019,1614:4-8+182............................................................................................52

[19] 秦高凤,王蓬文*.黄连解毒汤对糖尿病脑病和阿尔茨海默病的作用[J].中华中医药学刊,,:1-13..............................................................................................53

3. 循证评价方向

[20] 胡嘉元,张晓雨,赵晨,孙杨,陈诗琪,李承羽,刘硕,邱瑞瑾,田贵华,商洪才*.母方案设计用于冠心病中医药防治方案循证优化的思路和实施方法[J].中国循证医学杂志,2019,1901:102-106.............................................................................54

[21] 赵晨,田贵华,王燕平,李幼平,卞兆祥,商洪才*,王永炎.涵盖科学观与人文观的循证医学发展——兼谈循证中医药学科的未来前景[J].中国循证医学杂志,2019,1902:232-237.............................................................................................55

[22] 郑颂华,吴泰相,商洪才,李幼平,DouglasG.Altman,DavidMoher,卞兆祥.中药复方临床随机对照试验报告规范2017——CONSORT声明的扩展、说明与详述[J].中西医结合心脑血管病杂志,2019,1701:1-14...............................................56

[23] 王永炎,王燕平,张华敏,张占军,杨洪军,白卫国,商洪才,纪鑫毓.重视医德教育加强临床研究与时俱进[J].北京中医药大学学报,2019,4201:5-7.............57

[24] 张夏天,胡烨胤,张晓雨,陈荷清,王晓丽,李心怡,黄雨丝,林繄依,商洪才,卞兆祥,田贵华.2013～2017年发表的推拿系统评价的再评价[J].中国循证医学杂志,2019,1903:361-367.........................................................................................58

[25] 张晓雨,邱瑞瑾,李承羽,商洪才*.中医临床研究优先领域/主题设置思路与方法[J].中国循证医学杂志,2019,1903:373-376.................................................59

[26] 赵晨,田贵华,张晓雨,王燕平,卞兆祥,商洪才*,李幼平.循证医学向循证科学发展的内涵和思考[J].中国循证医学杂志,2019,1905:510-514.....................60

[27] 邱瑞瑾,陈诗琪,韩松洁,何天麦,黄涯,李敏,胡嘉元,孙杨,陈静,商洪才*.基于COMET数据库的核心指标集研究现状及进展[J].中国循证医学杂志,2019,1905:622-629.............................................................................................61

[28] 陈耀龙,商洪才,杨克虎,王辰.临床实践指南的国际经验和中国道路[J].协和医学杂志,2019,1003:289-292.............................................................................62

[29] 戴亮,郑颂华,田然,钟丽丹,李幼平,吕爱平,陈安文,商洪才,卞兆祥.规范中医药临床研究方案内容2018声明:建议、说明与详述[J].中国中西医结合杂志,2019,3906:739-749.............................................................................................63

[30] 王昊,杨秋莉,王子旭,杜渐,范逸品,商洪才,郭蓉娟,谢颖桢,孔军辉,张伯华,周荣新,贺苏,李春,王永炎.关于中医平行病历书写规范的建议[J].现代中医临床,2019,2603:6-10...............................................................................................64

[31] 陈耀龙,罗旭飞,王吉耀,刘晓清,商洪才,杨克虎.如何区分临床实践指南与专家共识[J].协和医学杂志,2019,1004:403-408.................................................65

[32] 李静,商洪才*,赵晨.药物临床试验质量监查的问题分析对策以及中成药上市后再评价领域监查问题[J].中国新药杂志,2019,2818:2184-2188.................66

[33] 陈耀龙,马艳芳,周奇,周英凤,吕兰婷,翟所迪,姚晨,商洪才,杨克虎,李幼平.谁应该参与临床实践指南的制订?[J].协和医学杂志,2019,1005:524-530...............................................................................................................................67

[34] 陶立元,刘珏,商洪才*.中医药疗效评价研究热点的双向聚类计量学分析[J].世界中医药,2019,1410:2568-2572.................................................................68

[35] 郑蕊,钟长鸣,关曼柯,陈诗琪,李承羽,商洪才*.中药独家品种说明书安全性信息的评价研究[J].世界中医药,2019,1410:2578-2581.................................69

[36] 邱瑞瑾,何天麦,黄涯,韩松洁,钟长鸣,胡嘉元,李敏,关曼柯,陈静,商洪才*.SWAT计划和MIROR项目介绍及其对循证中医药学发展的启示[J].世界中医药,2019,1410:2545-2551.........................................................................................70

[37] 李涵,孙杨,张晓雨,商洪才*.以证统病——中医临床思维的回归与创新[J].世界中医药,2019,1410:2552-2556+2562...............................................................71

[38] 陈耀龙,王健健,詹思延,孙剑,靳英辉,李慧,商洪才,杨克虎.如何应对指南制订中的利益冲突[J].协和医学杂志,2019,1006:685-691.................................72

[39] 钟晓莹,吴立群,陈睿哲, 周武，谷林，商洪才，张洪来.基于数据挖掘技术探析针灸治疗椎动脉型颈椎病随机对照临床试验的选穴规律[J].世界中医药,2019,14(10):2573-2577.DOI:10.3969/j.issn.1673-7202.2019.10.007..................................................................................................................................73

4. 中药药理及作用机制方向

[40] 宋珂,侯彦宏,苏都娜,杨会,白云绮,李慧,娄利霞,赵一舟,吴爱明,图雅,聂波*.四妙勇安汤对ApoE(-/-)动脉粥样硬化小鼠IL-6和MCP-1的影响[J].中国现代中药,2019,2104:441-447.............................................................................74

[41] 宋珂,侯彦宏,杨会,白云绮,李慧,聂波*.ApoE基因敲除小鼠疾病模型的研究进展[J].中国医药导报,2019,1618:42-44+48...................................................75

[42] 吴爽,张海艳,杨田田,岑锴,周东蕊,朱陵群*.注射用血塞通对SH-SY5Y细胞缺糖缺氧损伤模型Lingo-1表达的影响[J].中草药,2019,5016:3859-3865.............................................................................................................................76

[43] 巩卓彦,黄帅阳,陈芳,盛宁,冯慧利,董云芳,任映,杨金铎,王蓬文*.参枝苓口服液对App/Ps1双转基因小鼠早期海马突触和髓鞘改变的影响[J].中国实验动物学报,2019,2705:592-597.................................................................................77

[44] 黄帅阳,盛宁,陈芳,任映,杨金铎,王蓬文*.参枝苓口服液对APP/PS1双转基因小鼠海马α7-nAChRs和mGluR5表达的影响[J].北京中医药大学学报,2019,4203:198-204.............................................................................................78

[45] ShuangWu,PeiChen,Yihuai Zou,Lan Jiang,Hualei Geng,RuyuYan,ShanWang ,Lingqun Zhu*.Clinicalrelevance of Chinese syndrome factors and thromboela

stography levels in patients withphlegm-heat and fu-organ excess syndrome.

Journal of Traditional ChineseMedical Sciences. 2019,6,211-217.......................79

5. 药物分析方向

[46] 杨会,宋珂,李慧,白云绮,王淑琪,吴圣贤,陈立新,聂波*.四妙勇安汤活性部位配伍方薄层色谱鉴别及绿原酸和哈巴俄苷的含量测定[J].中国现代中药,2019,2105:668-672.............................................................................................80

6. 中医理论方法

[47] 张楠楠,赵晨,商洪才,陈静,时晓迟.中医药干预原发性高血压伴焦虑抑郁研究进展[J].西部中医药,2019,3201:135-139.....................................................81

[48] 胡嘉元,邱瑞瑾,赵晨,石兆峰,关曼柯,代倩倩,商洪才*.以病机为主导的中医临床个体化评价方法初探[J].世界中医药,2019,1410:2563-2567.................82

[49] 李亚欢,张冬梅,王淑艳,王飞,赵冉冉,陈健,陈萌. 脾虚证动物模型研制概况[J].中医药导报,2019,25(01):100-102...........................................................83

[50] 王飞,陈萌,赵冉冉,李丽娜,张冬梅,王梦薇,王启航. 气候变迁对中医学发展的影响[J].中华中医药杂志,2019,34(09):4401-4404...................................84

[51] 张迪,陈萌,张冬梅,李丽娜,陆瑞敏,邹天远,王梦薇,王启航. 《伤寒论》中炙甘草应为今之炒甘草[J]. 环球中医药,2019,12(11):1672-1674...............85

[52] 陈萌,张迪,许宗颖,张冬梅. 中医气论的内涵与出路[J].医学与哲学,2019,40(21):79-81.............................................................................................86

7. 肾脏病、内分泌、风湿免疫方向

[53] 孟晓莹,柴立民,王长志,陈贺宁,邓培颖,李雪,美依尔·欢地克,张慧杰,韦杰*.黄芪、当归、忍冬藤水提冻干粉组合对白细胞介素1β诱导大鼠T细胞亚群增殖与分化的影响[J].环球中医药,2019,1208:1154-1159.............................87

[54] 陈琪,王玉洁,李世超,周静威*,柴立民.中西医结合治疗类风湿关节炎活动期疗效观察及免疫机制研究[J].VIP学报,2019,3612:1875-1881......................88

[55] 黄为钧,赵进喜,王世东,肖永华,傅强,张华,吴文静,申子龙,宫晴.祛风通络方对糖尿病肾脏病模型大鼠足细胞损伤的影响[J].中医杂志,2019,6005:422-426...............................................................................................................................89

[56] 冯振东,贾奇,姜韩雪,韩雪婷,朱泽兵,侠晨辉,刘玉宁,刘伟敬.“益气养阴通络法”通过调控α-klotho延缓DKD进展的研究[J].中国中西医结合肾病杂志,2019,2002:105-108.............................................................................................90

[57] 崔海兰,马昀,宋越,黄小桐,孙莉娜,冯贺妍,刘玉宁,刘伟敬*.疏利分消方治疗钙调神经磷酸酶抑制剂所致慢性肾损伤的膜性肾病临床观察[J].中国中西医结合肾病杂志,2019,2002:141-144.....................................................................91

[58] 庞婉霞,朱泽兵,侠晨辉,叶霖,刘华锋,刘玉宁,刘伟敬*.白藜芦醇联合二苯乙烯苷通过抗衰老延缓糖尿病肾病进展的研究[J].中国中西医结合肾病杂志,2019,2005:383-386.............................................................................................92

[59] 刘伟敬,章友康.为进一步提高膜性肾病的缓解率而努力[J].内科急危重症杂志,2019,2504:265-267.........................................................................................93

[60] 冯贺妍,孙莉娜,程华,崔海兰,肖跃飞,刘伟敬*,刘玉宁.刘玉宁教授治疗多发性骨髓瘤肾损害的临床经验[J].中国中西医结合肾病杂志,2019,2007:565-567...............................................................................................................................94

[61] 黄一珊,符馨文,王旭,侠晨辉,刘伟敬*,刘玉宁.从“肾络三态论”探讨糖尿病肾病的临床辨治[J].中国中西医结合肾病杂志,2019,2006:559-561.........95

[62]Wei-Jun Huang, Tao Yangb, Chuan-Jiang Liub, Yong-Hua Xiaob, Qiang Fub, QingGongb, Hua Zhangb, Fan Shaob, Hong Yueb, Shi-Dong Wangb, Jin-XiZhao.Traditional Chinese Medicine Based on Zheng Differentiation versusAngiotensin Receptor Blocker/Angiotensin-converting Enzyme Antagonist inEfficacy of Treating Diabetic Kidney Disease: A Meta-analysis of RandomizedClinical Trials.World J Tradit Chin Med.2019,5(1).....................................................96